BioNTech SE
BNTX · NASDAQ Global Select · USD
87,51USD
0,00 (0,00 %)Stand 9. Nov., 21:00
Vorbörslich87,02−0,49 (−0,56 %)4:07 ET
Kennzahlen
- Eröffnung
- 88,08
- Vortag
- 87,51
- Tagesspanne
- 86,56 – 88,78
- 52 Wochen
- 79,52 – 124,00
- Volumen
- 1,11 Mio.
- Ø Volumen
- 1,14 Mio.
- Börsenwert
- 21,7 Mrd. $
- KGV
- -13,1
- Gewinn je Aktie (TTM)
- -5,88
- Dividendenrendite
- 0,0 %
- Beta
- 1,3
- Nächste Zahlen
- 9. März 2027
Finanzen
| EUR | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 2,76 Mrd. | 2,75 Mrd. | 3,82 Mrd. | 17,31 Mrd. | 18,98 Mrd. |
| Herstellungskosten | 616,47 Mio. | 541,3 Mio. | 599,8 Mio. | 3 Mrd. | 2,91 Mrd. |
| Bruttogewinn | 2,14 Mrd. | 2,21 Mrd. | 3,22 Mrd. | 14,32 Mrd. | 16,07 Mrd. |
| Forschung und Entwicklung | 2,02 Mrd. | 2,25 Mrd. | 1,78 Mrd. | 1,54 Mrd. | 949,2 Mio. |
| Vertrieb und Verwaltung | 698,2 Mio. | 599 Mio. | 557,7 Mio. | 541,2 Mio. | 327,2 Mio. |
| Operatives Ergebnis | −623,87 Mio. | −1,31 Mrd. | 690,4 Mio. | 12,64 Mrd. | 15,28 Mrd. |
| EBITDA | −628 Mio. | −367,1 Mio. | 1,38 Mrd. | 13,1 Mrd. | 15 Mrd. |
| Nettogewinn | −1,09 Mrd. | −665,3 Mio. | 930,3 Mio. | 9,43 Mrd. | 10,29 Mrd. |
| Gewinn je Aktie (verwässert) | -4,51 | -2,77 | 3,83 | 37,09 | 41,21 |
Umsatz nach Segment
Produkte · FY 2025
- Other Sales261,6 Mio. €100,00 %−17,99 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES1,79 Mrd. €62,54 %−2,86 %
- GERMANY759,1 Mio. €26,45 %+7,38 %
- IRELAND304,8 Mio. €10,62 %
- Rest of the World11,1 Mio. €0,39 %−94,35 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- -13,1
- Kurs-Umsatz-Verhältnis
- 7,9
- Kurs-Buchwert-Verhältnis
- 1,1
- PEG
- 0,1
- Bruttomarge
- 67,9 %
- Operative Marge
- −63,1 %
- Nettomarge
- −61,5 %
- Verschuldungsgrad
- 0,0
- EV/EBITDA
- -21,7
- Eigenkapitalrendite
- −8,1 %
- Kapitalrendite (ROIC)
- −8,3 %
- Free-Cashflow-Rendite
- −2,5 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 77,6 % | 80,3 % | 84,3 % | 82,7 % | 84,7 % |
| Operative Marge | −22,6 % | −47,8 % | 18,1 % | 73,0 % | 80,5 % |
| Nettomarge | −39,6 % | −24,2 % | 24,4 % | 54,5 % | 54,2 % |
| KGV | -18,0 | -39,7 | 24,7 | 3,7 | 5,2 |
| Kurs-Umsatz-Verhältnis | 7,1 | 9,6 | 6,0 | 2,0 | 2,9 |
| Kurs-Buchwert-Verhältnis | 1,0 | 1,4 | 1,1 | 1,7 | 4,7 |
| Verschuldungsgrad | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Liquidität 3. Grades | 7,5 | 7,5 | 9,4 | 7,4 | 4,3 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 1,4 % | 0,0 % |
| Unternehmenswert | 12,18 Mrd. | 16,95 Mrd. | 11,53 Mrd. | 20,47 Mrd. | 53,93 Mrd. |
| EV/EBITDA | -19,4 | -46,2 | 8,4 | 1,6 | 3,6 |
| Eigenkapitalrendite | −5,7 % | −3,4 % | 4,6 % | 47,0 % | 86,5 % |
| Kapitalrendite (ROIC) | −3,1 % | −6,4 % | 2,6 % | 45,2 % | 83,8 % |
| Free-Cashflow-Rendite | 1,4 % | −0,9 % | 20,3 % | 38,7 % | 1,3 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +0,2 % | −28,0 % | −77,9 % | −8,8 % | +3.834,6 % |
| Bruttogewinn | −3,2 % | −31,4 % | −77,5 % | −10,9 % | +3.697,9 % |
| Operatives Ergebnis | +52,5 % | −290,4 % | −94,5 % | −17,3 % | +18.648,3 % |
| Nettogewinn | −64,0 % | −171,5 % | −90,1 % | −8,3 % | +67.613,8 % |
| Gewinn je Aktie | −62,8 % | −172,3 % | −89,7 % | −10,0 % | +72.198,2 % |
| Freier Cashflow | +210,3 % | −105,2 % | −64,7 % | +1.696,1 % | +843,9 % |
| Dividende je Aktie | 0,0 % | 0,0 % | −100,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 20Kaufen
- 4Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
120,33
Durchschnitt · +37,50 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 1,87 Mrd. | 1,87 Mrd. | 2,3 Mrd. |
| Umsatz (Tief – Hoch) | 1,54 Mrd. – 2,17 Mrd. | 1,67 Mrd. – 2,05 Mrd. | 1,34 Mrd. – 2,97 Mrd. |
| Gewinn je Aktie (Ø) | -5,74 | -5,65 | -4,59 |
| Gewinn je Aktie (Tief – Hoch) | -6,22 – -5,24 | -5,77 – -5,53 | -7,96 – -1,27 |
| Analysten | 6 | 9 | 10 |
Letzte Änderungen
- HC Wainwright & Co.9. Nov. 2026Buy
- Evercore ISI Group4. Nov. 2026Outperform
- Wells Fargo4. Nov. 2026Overweight
- Morgan Stanley4. Nov. 2026Overweight
- UBS4. Nov. 2026Buy
- Canaccord Genuity14. Okt. 2026Buy
- Morgan Stanley7. Okt. 2026Overweight
- BMO Capital8. Sept. 2026Outperform → Market Perform
Quartalszahlen
Nächste Zahlen: 9. März 2027| Nov. 2026 | Aug. 2026 | Mai 2026 | März 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | März 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,76 | -2,40 | -2,54 | -0,22 | -1,12 | -2,69 | -2,48 | 0,46 |
| Gewinn je Aktie · Tatsächlich | 0,83 | -3,70 | -2,43 | -1,44 | -0,14 | -1,82 | -1,82 | 1,15 |
| Abweichung | +9,25 % | −54,29 % | +4,42 % | −556,70 % | +87,47 % | +32,32 % | +26,55 % | +148,70 % |
| Umsatz · Tatsächlich | 1,46 Mrd. | 120,6 Mio. | 136,45 Mio. | 1,07 Mrd. | 1,78 Mrd. | 307,08 Mio. | 200,39 Mio. | 1,23 Mrd. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 2. Juni 2022 | 17. Juni 2022 | 2,11 |
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 18,61 %
- Investoren mit 13F-Meldung
- 320
Größte Investoren
- FMR LLC2,99 %7,57 Mio.
- PRIMECAP MANAGEMENT CO/CA/1,49 %3,77 Mio.
- DODGE & COX1,45 %3,68 Mio.
- FLOSSBACH VON STORCH SE0,88 %2,23 Mio.
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC.0,82 %2,07 Mio.
- BLACKROCK, INC.0,73 %1,85 Mio.
- TEMASEK HOLDINGS (PRIVATE) LTD0,59 %1,51 Mio.
- BNP PARIBAS FINANCIAL MARKETS0,52 %1,32 Mio.
Insider-Geschäfte
- Sahin Ugur9. Okt. 2026 · 10 percent owner, officer: Chief Executive OfficerVerkauf36.209 Aktien · 95,37
- Sahin Ugur8. Okt. 2026 · 10 percent owner, officer: Chief Executive OfficerVerkauf27.000 Aktien · 92,31
- Sahin Ugur7. Okt. 2026 · 10 percent owner, officer: Chief Executive OfficerVerkauf24.000 Aktien · 95,86
- Sahin Ugur6. Okt. 2026 · 10 percent owner, officer: Chief Executive OfficerVerkauf21.000 Aktien · 96,81
- Sahin Ugur5. Okt. 2026 · 10 percent owner, officer: Chief Executive OfficerVerkauf72.000 Aktien · 97,23
- Sahin Ugur2. Okt. 2026 · 10 percent owner, officer: Chief Executive OfficerVerkauf17.000 Aktien · 96,72
- Sahin Ugur1. Okt. 2026 · 10 percent owner, officer: Chief Executive OfficerVerkauf17.000 Aktien · 97,46
- Sahin Ugur30. Sept. 2026 · 10 percent owner, officer: Chief Executive OfficerVerkauf32.000 Aktien · 98,12
Vergleichbare Unternehmen
Über das Unternehmen
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Führung
- Ugur SahinCo-Founder, Chief Executive Officer & Chair of the Management Board
- Ramon Zapata-GomezChief Financial Officer & Member of Management Board
- Annemarie HanekampChief Commercial Officer & Member of Management Board
- James Timothy Patrick RyanChief Legal & Business Officer and Member of the Management Board
- Sierk PöttingMD, Chief Operating Officer & Member of Management Board
- Ozlem TureciCo-Founder, Chief Medical Officer & Member of Management Board
- CEO
- Ugur Sahin
- Mitarbeitende
- 7.807
- Hauptsitz
- Mainz, RP, DE
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 10. Okt. 2019
- Website
- biontech.com/de/de/home.html
Nachrichten
- The Motley Fool · 9. Nov., 5:00BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era.
- 24/7 Wall Street · 6. Nov., 11:05Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
- The Motley Fool · 5. Nov., 14:17Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?
- Seeking Alpha · 4. Nov., 9:30BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)
- Seeking Alpha · 3. Nov., 16:16BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript
- MarketBeat · 3. Nov., 13:17BioNTech Q3 Earnings Call Highlights
- GlobeNewsWire · 3. Nov., 6:45BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
- 24/7 Wall Street · 28. Okt., 12:04Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
- Investopedia · 26. Okt., 16:01Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
- 24/7 Wall Street · 26. Okt., 9:14Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.